Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Oct 16, 2025; 17(10): 111259
Published online Oct 16, 2025. doi: 10.4253/wjge.v17.i10.111259
Published online Oct 16, 2025. doi: 10.4253/wjge.v17.i10.111259
Challenges in evaluating high-grade pancreato-hepato-biliary neuroendocrine tumors
Payila Satya Raghava Aneesh, Venkatesh Vaithiyam, Department of Gastroenterology, Govind Ballabh Pant Institute of Post Graduate Medical Education and Research, New Delhi 110002, India
Author contributions: Aneesh PSR wrote the original draft; Vaithiyam V contributed to conceptualization, writing, reviewing, and editing; Aneesh PSR and Vaithiyam V participated in the manuscript drafting. All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Venkatesh Vaithiyam, Assistant Professor, Department of Gast
Received: June 26, 2025
Revised: July 17, 2025
Accepted: September 11, 2025
Published online: October 16, 2025
Processing time: 111 Days and 20.4 Hours
Revised: July 17, 2025
Accepted: September 11, 2025
Published online: October 16, 2025
Processing time: 111 Days and 20.4 Hours
Core Tip
Core Tip: The pancreato-hepatobiliary neuroendocrine tumors are rare, heterogeneous neoplasms. Therefore, individual tumor prognosis prediction is essential. Although various clinicopathological factors influence the aggressiveness of tumors, no single factor can accurately predict prognosis. Hence, efforts towards the development of novel markers, such as identifying gene mutations and the tumor microenvironment in biopsy specimens, would have brought new research insights.